Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 910 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 Load more HOT NEWS For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer Mom Walks In To Comfort Scared Son After Surgery And Sees... EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin
